ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Keyword Index

Click a keyword to view all the abstracts on this site tagged with that keyword.

  • juvenile dermatomyositis and proteomics
  • juvenile dermatomyositis and pulmonary complications
  • juvenile dermatomyositis and race/ethnicity
  • juvenile dermatomyositis and remission
  • juvenile dermatomyositis and rituximab
  • juvenile dermatomyositis and scleroderma
  • juvenile dermatomyositis and skin
  • Juvenile dermatomyositis and treatment
  • juvenile dermatomyositis and vasculitis
  • Juvenile idiopathic arthritis
  • juvenile idiopathic arthritis (JIA)
  • juvenile idiopathic arthritis (JIA) and access to care
  • juvenile idiopathic arthritis (JIA) and administrative databases
  • juvenile idiopathic arthritis (JIA) and anti-TNF therapy
  • juvenile idiopathic arthritis (JIA) and juvenile idiopathic arthritis-enthesitis (ERA)
  • juvenile idiopathic arthritis (JIA) and juvenile myositis
  • juvenile idiopathic arthritis (JIA) and lipids
  • juvenile idiopathic arthritis (JIA) and longitudinal studies
  • Juvenile idiopathic arthritis (JIA) and macrophage activation syndrome
  • juvenile idiopathic arthritis (JIA) and magnetic resonance imaging (MRI)
  • Juvenile idiopathic arthritis (JIA) and major histocompatibility complex (MHC)
  • juvenile idiopathic arthritis (JIA) and malignancy
  • juvenile idiopathic arthritis (JIA) and meta-analysis
  • juvenile idiopathic arthritis (JIA) and methotrexate (MTX)
  • juvenile idiopathic arthritis (JIA) and microbiome
  • juvenile idiopathic arthritis (JIA) and monocytes
  • juvenile idiopathic arthritis (JIA) and musculoskeletal pain
  • juvenile idiopathic arthritis (JIA) and natural killer (NK) cells
  • juvenile idiopathic arthritis (JIA) and neutrophils
  • Juvenile idiopathic arthritis (JIA) and nonsteroidal antiinflammatory drugs (NSAIDs)
  • juvenile idiopathic arthritis (JIA) and nutrition
  • Juvenile idiopathic arthritis (JIA) and opportunistic infections
  • juvenile idiopathic arthritis (JIA) and oral
  • juvenile idiopathic arthritis (JIA) and outcome measures
  • Juvenile idiopathic arthritis (JIA) and outcomes
  • juvenile idiopathic arthritis (JIA) and ovarian
  • juvenile idiopathic arthritis (JIA) and pain
  • juvenile idiopathic arthritis (JIA) and pathogenesis
  • juvenile idiopathic arthritis (JIA) and patient
  • juvenile idiopathic arthritis (JIA) and patient outcomes
  • juvenile idiopathic arthritis (JIA) and patient preferences
  • Juvenile idiopathic arthritis (JIA) and patient-reported outcome measures
  • juvenile idiopathic arthritis (JIA) and pediatric rheumatology
  • juvenile idiopathic arthritis (JIA) and pediatrics
  • juvenile idiopathic arthritis (JIA) and physical activity
  • juvenile idiopathic arthritis (JIA) and physical function
  • juvenile idiopathic arthritis (JIA) and polyarthritis
  • juvenile idiopathic arthritis (JIA) and polymorphism
  • juvenile idiopathic arthritis (JIA) and population studies
  • juvenile idiopathic arthritis (JIA) and positron emission tomography (PET)
  • Juvenile idiopathic arthritis (JIA) and pregnancy
  • juvenile idiopathic arthritis (JIA) and prescribing trends
  • Juvenile idiopathic arthritis (JIA) and proteomics
  • juvenile idiopathic arthritis (JIA) and psoriasis
  • Juvenile idiopathic arthritis (JIA) and quality measures
  • juvenile idiopathic arthritis (JIA) and quality of life
  • Juvenile idiopathic arthritis (JIA) and race/ethnicity
  • juvenile idiopathic arthritis (JIA) and radiography
  • juvenile idiopathic arthritis (JIA) and registries
  • juvenile idiopathic arthritis (JIA) and registry
  • juvenile idiopathic arthritis (JIA) and regulatory cells
  • juvenile idiopathic arthritis (JIA) and remission
  • juvenile idiopathic arthritis (JIA) and rheumatoid arthritis (RA)
  • juvenile idiopathic arthritis (JIA) and safety
  • juvenile idiopathic arthritis (JIA) and self-management
  • Juvenile idiopathic arthritis (JIA) and shared dicision making
  • juvenile idiopathic arthritis (JIA) and spondylarthropathy
  • juvenile idiopathic arthritis (JIA) and statistical methods
  • juvenile idiopathic arthritis (JIA) and synovial cells
  • juvenile idiopathic arthritis (JIA) and synovial fluid
  • juvenile idiopathic arthritis (JIA) and synovitis
  • juvenile idiopathic arthritis (JIA) and systemic lupus erythematosus (SLE)
  • juvenile idiopathic arthritis (JIA) and T cell repertoire
  • juvenile idiopathic arthritis (JIA) and technology
  • Juvenile idiopathic arthritis (JIA) and temporomandibular joint
  • juvenile idiopathic arthritis (JIA) and therapy
  • juvenile idiopathic arthritis (JIA) and tocilizumab
  • juvenile idiopathic arthritis (JIA) and treatment
  • juvenile idiopathic arthritis (JIA) and treatment options
  • juvenile idiopathic arthritis (JIA) and tuberculosis
  • juvenile idiopathic arthritis (JIA) and tumor necrosis factor (TNF)
  • juvenile idiopathic arthritis (JIA) and ultrasonography
  • Juvenile idiopathic arthritis (JIA) and ultrasound
  • Juvenile idiopathic arthritis (JIA) and uveitis
  • juvenile idiopathic arthritis (JIA) and vaccines
  • Juvenile idiopathic arthritis-enthesitis (ERA)
  • juvenile idiopathic arthritis-enthesitis (ERA) and juvenile spondylarthropathy
  • juvenile idiopathic arthritis-enthesitis (ERA) and neutrophils
  • juvenile idiopathic arthritis-enthesitis (ERA) and oral
  • juvenile idiopathic arthritis-enthesitis (ERA) and outcome measures
  • Juvenile idiopathic arthritis-enthesitis (ERA) and outcomes
  • juvenile idiopathic arthritis-enthesitis (ERA) and pathogenesis
  • juvenile idiopathic arthritis-enthesitis (ERA) and pediatric rheumatology
  • juvenile idiopathic arthritis-enthesitis (ERA) and polyarthritis
  • juvenile idiopathic arthritis-enthesitis (ERA) and registry
  • juvenile idiopathic arthritis-enthesitis (ERA) and remission
  • juvenile idiopathic arthritis-enthesitis (ERA) and safety
  • juvenile idiopathic arthritis-enthesitis (ERA) and spondylarthritis
  • juvenile idiopathic arthritis-enthesitis (ERA) and synovial cells
  • juvenile idiopathic arthritis-enthesitis (ERA) and synovial fluid
  • juvenile idiopathic arthritis-enthesitis (ERA) and temporomandibular joint
  • Juvenile idiopathic arthritis-enthesitis (ERA) and treatment options
  • juvenile idiopathic arthritis-enthesitis (ERA) and tumor necrosis factor (TNF)
  • Juvenile Inflammatory Arthritis
  • juvenile myositis
  • juvenile myositis and myopathy
  • juvenile myositis and myositis
  • juvenile myositis and outcomes
  • juvenile myositis and pathogenesis
  • Juvenile myositis and patient engagement
  • juvenile myositis and pediatric rheumatology
  • juvenile myositis and prognostic factors
  • Juvenile Rheumatoid Arthritis
  • Juvenile Sacroiliitis
  • Juvenile scleroderma
  • juvenile scleroderma and juvenile idiopathic arthritis (JIA)
  • Juvenile scleroderma and juvenile sclerosis
  • juvenile scleroderma and morphea
  • juvenile scleroderma and myopathy
  • juvenile scleroderma and outcomes
  • Juvenile scleroderma and pediatric rheumatology
  • juvenile scleroderma and systemic sclerosis
  • Juvenile sclerosis
  • Juvenile sclerosis and pediatric rheumatology
  • juvenile sclerosis and Pulmonary Involvement
  • juvenile sclerosis and systemic sclerosis
  • juvenile SLE
  • juvenile SLE and activity score
  • juvenile SLE and genetics
  • juvenile SLE and Intervention
  • Juvenile SLE and morbidity and mortality
  • juvenile SLE and pediatric rheumatology
  • juvenile SLE and performance
  • juvenile SLE and randomized trials
  • juvenile SLE and renal disease
  • Juvenile SLE and systemic lupus erythematosus (SLE)
  • juvenile SLE and thrombocytopenia
  • juvenile spondylarthropathy
  • juvenile spondylarthropathy and juvenile arthritis
  • juvenile spondylarthropathy and pediatric rheumatology
  • juvenile spondylarthropathy and prognostic factors
  • juvenile spondylarthropathy and spondylarthropathy
  • Juvenile Spondyloarthritis
  • Kawasaki disease
  • Kawasaki disease and aspirin
  • Kawasaki disease and epidemiologic methods
  • Kawasaki disease and intravenous immunoglobulin (IVIG)
  • Kawasaki disease and Nail
  • Kawasaki disease and polymorphism
  • kENYA
  • keratinocyte
  • Keratinocytes
  • Kezar
  • kid
  • Kidney
  • Kidney and amyloidosis
  • Kidney and complement
  • Kidney and crystal-induced arthritis
  • Kidney and gout
  • Kidney and Plasmablasts
  • Kidney and rheumatoid arthritis (RA)
  • Kidney and Sjogren's syndrome
  • Kidney and SLE
  • Kidney and therapeutic targeting
  • Kidney and tumor necrosis factor (TNF)
  • Kidney and uric acid
  • kidney disease
  • Kidney function
  • Kidney stiffness
  • kidney transplant recipients
  • kinase
  • kinase and monocytes
  • kinase and mouse model
  • kinase and osteoclasts
  • kinase and rheumatoid arthritis
  • kinase and rheumatoid arthritis (RA)
  • kinase and rheumatologic disease
  • kinase and signal transduction
  • kinase and syk
  • kinase and systemic sclerosis
  • KIR (Killer Ig like receptor)
  • KL-6 and pulmonary function test
  • KLRG1
  • Knee
  • Knee and arthrocentesis
  • Knee and cartilage
  • Knee and clinical trials
  • Knee and epidemiology
  • Knee and health care cost
  • Knee and Hip
  • Knee and injury
  • Knee and meniscus
  • Knee and MRI
  • Knee and OA
  • Knee and osteoarthritis
  • Knee and pain
  • Knee and physical activity
  • Knee OA and Molecular weight
  • Knee osteoarthritis
  • knee pain
  • First |
  • « Previous Page
  • 29
  • 30
  • 31
  • 32
  • 33
  • [34]
  • 35
  • 36
  • 37
  • 38
  • 39
  • Next Page »
  • | Last
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology